Breakthrough Stool Test Offers Hope for Chronic Diarrhoea Patients in India
A groundbreaking study led by researchers from the All India Institute of Medical Sciences (AIIMS) and other premier medical centres has unveiled a simple stool test that could transform the diagnosis of a frequently missed cause of chronic diarrhoea. Published in the Indian Journal of Gastroenterology, this research promises to end years of diagnostic uncertainty for countless patients suffering from persistent gastrointestinal issues.
Unveiling a Hidden Culprit: Bile Acid Malabsorption
Chronic diarrhoea affects approximately 8–10% of the Indian population, with the majority of cases attributed to functional bowel disorders like irritable bowel syndrome (IBS). However, a significant subset of these patients may actually have bile acid malabsorption (BAM), a condition that often goes undiagnosed due to the complexity and limited availability of existing tests.
Dr. Govind K. Makharia, from the Department of Gastroenterology and Human Nutrition at AIIMS, emphasized the importance of this discovery. "With newer spot stool tests, it is now possible to identify these cases more easily and tailor treatment accordingly, potentially improving outcomes for many who have struggled without a clear diagnosis," he stated.
Study Methodology and Diagnostic Precision
The study focused on measuring fecal bile acids (FBA) using a straightforward assay, establishing a clear diagnostic threshold. Researchers identified an FBA level of 2.8 µg/g as the cut-off point, which demonstrated high sensitivity (89.5%) and specificity (92%) in detecting BAM. This indicates robust diagnostic performance, making the test a reliable tool for clinical use.
By comparing healthy individuals with patients suffering from various intestinal diseases, the study found markedly elevated bile acid levels in those affected by BAM. When applied to real-world patient groups, the results were particularly revealing:
- Around 21% of patients with IBS-related diarrhoea or functional diarrhoea were diagnosed with BAM.
- The proportion surged to 57% among individuals who had undergone gallbladder removal.
- Over 54% of patients with intestinal tuberculosis also exhibited signs of BAM.
Implications for Patient Care and Treatment
These findings suggest that a substantial number of patients currently being treated for other causes of chronic diarrhoea may have an underlying, treatable condition that is being overlooked. Without accurate diagnosis, patients often endure ongoing symptoms despite treatment, leading to repeated medical consultations and a diminished quality of life.
The primary advantage of this new diagnostic approach lies in its simplicity. Unlike existing methods that are technically demanding and confined to specialized centres, this test can be performed on a single stool sample, making it far more accessible for routine clinical practice.
Future Prospects and Broader Impact
Experts believe that wider adoption of this stool test could facilitate earlier identification of hidden BAM cases, enabling more targeted and effective treatments. This advancement holds the potential to reduce healthcare costs associated with misdiagnosis and improve patient outcomes across India.
As the medical community embraces this innovative testing method, it marks a significant step forward in gastroenterology, offering new hope for those grappling with the debilitating effects of chronic diarrhoea.
